EU announced negotiating with pharmaceutical companies to raise the amount of supplied coronavirus vaccines with Valneva, Novavax and Moderna. EU wants to increase its reserves of vaccine beyond 2.3 billion doses which it has already secured from six pharmaceutical firms.
Currently, the EU wants to deal with covid-19 vaccine makers to allow the EU to gain access to possible upgraded vaccines that may offer improved protection against mutations of the coronavirus. The anti-variant clause was included in a second deal finalised earlier in February with Pfizer and BioNTech for the supply of 300 million additional anti COVID-19 doses. According to tests, the Pfizer vaccine is effective against the British and the South African mutations of coronavirus. The corporation is also developing the booster shot that would be tailored against mutations.
Performance of Pfizer’s shares (Tradingview.com)